DR. MAQBOOL ALAM HALEPOTA M.D. NPI 1558384966

NPI Details

DR. Maqbool Alam Halepota, M.D. is a medical oncology internal medicine in Glendale, AZ with 40 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. DR. Maqbool Alam Halepota, M.D. NPI is 1558384966. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

5601 W EUGIE AVE STE 106
GLENDALE, AZ
ZIP 85304-256
Phone: (602) 978-6255
Fax: (602) 564-9286

The NPI 1558384966 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, heparin sodium, (heparin lock flush), per 10 units (HCPCS:J1642)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, romiplostim, 10 micrograms (HCPCS:J2796)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Ferritin (blood protein) level (HCPCS:82728)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Injection of drug or substance into vein (HCPCS:96374)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Infusion, normal saline solution, 250 cc (HCPCS:J7050)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Unclassified drugs (HCPCS:J3490)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Biopsy and aspiration of bone marrow sample for diagnosis (HCPCS:38222)
• Injection, lorazepam, 2 mg (HCPCS:J2060)

The enumeration date for this NPI number is 7/26/2006 and was last updated on 7/9/2017.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.